New appointment at Ascletis Pharma Inc.
Commercial-stage biotechnology company Ascletis Pharma Inc., which works to address unmet medical needs, has announced that Dr Lindi Tan has joined the company as Chief Financial Officer. Dr Tan previously held roles at SeaTown Holdings International, where she was Global Healthcare Analyst and responsible for driving multi-asset investments, and Temasek International, where she held an investment role in the Life Sciences team and was the Staff Officer to the Chief Investment Officers/Heads of Investments.
“We are very pleased to welcome Lindi to the management team,” said Dr Jinzi J. Wu, Founder, Chairman and CEO of Ascletis. "She brings to Ascletis more than 15 years of investment, finance, research and management experience in the global healthcare sector and has a proven track record of healthcare investing and partnering. Her extensive experience, leadership, and familiarity with our business makes her an ideal choice to help lead Ascletis as we move on to the next phase of our transformation.”
Dr Tan said: “I am extremely excited to be joining Ascletis at this crucial time as the Company moves ahead to execute on to the next stage of growth. I look forward to working with Dr Wu and the team to implement our strategy and deliver shareholder value.”